Bookmark

Add to MyYahoo RSS

BioCryst Pharmaceuticals News

News on BioCryst Pharmaceuticals (Ticker: BCRX) continually updated from thousands of sources around the net.

Saturday | The News-Star

Single-dose, injected flu treatment shows promiseSingle-dose,...

Single-dose, injected flu treatment shows promise A new single-dose, injected drug appears safe and effective at helping ease flu symptoms. Check out this story on thenewsstar.com: http://tnsne.ws/1s1uhzp In this photo, a nurse is administering an intramuscular injection into the left shoulder muscle of a 13-year old boy as his mother looks on.

Comment?

Related Topix: Medicine, Influenza, Health, Infectious Diseases, University of Alabama, Biotech, Healthcare Industry, Centers for Disease Control and Prevention

Mon Sep 08, 2014

HIV and Hepatitis

ICAAC 2014: Single Dose of Flu Drug Peramavir Looks Safe and Effective

A single dose of the investigational neuraminidase inhibitorperamavir administered within 2 days after symptom onset lowered influenza viral load and reduced duration of symptoms including fever, according to study findings presented at the the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy this week in Washington, DC. Peramivir, developed by BioCryst Pharmaceuticals, is a potent injected neuraminidase inhibitor with in vitro activity against all influenza virus subtypes.

Comment?

Related Topix: Medicine, Influenza, Health, Biotech, Healthcare Industry, University of Alabama, Infectious Diseases

Sat Sep 06, 2014

HON

Single-Dose, Injected Flu Treatment Shows Promise

The studies included a total of 427 adults who were given one injection of the drug peramivir or a placebo within 48 hours of the start of flu symptoms. Compared to those given the "dummy" injection, patients who received the drug were symptom-free a median of 22 hours sooner, and fever-free 24 hours sooner, the studies found.

Comment?

Related Topix: Health, Medicine, Influenza, Infectious Diseases, Mount Kisco, NY, University of Alabama, Biotech, Healthcare Industry, Microbiology, Biology, Science

GlobeNewswire

BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting

BioCryst Pharmaceuticals, Inc. today announced trial results related to RAPIVAB , a neuraminidase inhibitor for the treatment of influenza at the Interscience Conference on Antimicrobial Agents & Chemotherapy in Washington, D.C., September 5-9, 2014. "Based on clinical trial data, peramivir is the first neuraminidase inhibitor that has shown to be safe and effective as a single-dose therapy for patients with acute, uncomplicated influenza," said presenting author Richard Whitley, M.D , University of Alabama at Birmingham.

Comment?

Related Topix: Medicine, Influenza, Health, Biotech, Healthcare Industry, University of Alabama, Pharmacology, H1N1 Influenza / Swine Flu

Thu Sep 04, 2014

BioSpace

Biocryst Pharmaceuticals Participates In World Health Organization...

RESEARCH TRIANGLE PARK, N.C., Sept. 4, 2014 -- BioCryst Pharmaceuticals, Inc. today announced its participation in a consultation on potential Ebola therapies and vaccines hosted by the World Health Organization .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Food and Drug Administration

Wed Sep 03, 2014

BioSpace

Biocryst Pharmaceuticals To Present At Rodman & Renshaw Conference

BioCryst Pharmaceuticals, Inc. today announced that its executives are scheduled to present a corporate summary and update regarding the Company's development programs at the Rodman & Renshaw 16th Annual Investment Conference in New York on Wednesday, September 10, 2014 at 10:50 a.m. Eastern Time.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Financial Services, Investment Banking, Rodman and Renshaw

Business Journal

Durham's BioCryst defaults on loan after poor sales of flu drug in Japan

BioCryst had expected the default to happen, so some the fallout was already backed in to the share price, which still close at $12.86, near the 52-week high of $14.62, largely because BioCryst is developing a drug that could fight the Ebola virus .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Tue Sep 02, 2014

GlobeNewswire

BioCryst to Present Peramivir Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting

BioCryst Pharmaceuticals, Inc. today announced the presentation of trial results related to intravenous peramivir for the treatment of influenza at the Interscience Conference on Antimicrobial Agents & Chemotherapy in Washington, D.C., September 5-9, 2014.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Influenza, Health, H1N1 Influenza / Swine Flu

Fri Aug 29, 2014

AmericanBankingNews.com

Insider Selling: Thomas R. Staab II Sells 10,000 Shares of BioCryst Pharmaceuticals Stock

BioCryst Pharmaceuticals CFO Thomas R. Staab II unloaded 10,000 shares of the stock in a transaction dated Wednesday, August 27th.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

BioSpace

Biocryst Pharmaceuticals Expected To Jump Into Ebola Race In A Few Weeks

BioCryst Pharmaceuticals, Inc. today announced that the National Institute of Allergy and Infectious Diseases has awarded a contract modification for an additional $2.4 million to BioCryst to conduct a dose ranging efficacy study of an intramuscular formulation of BCX4430 in non-human primates as a treatment for Ebola virus disease.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Infectious Diseases, National Institutes of Health

Local Tech Wire

US to begin tests of GSK's Ebola vaccine next week

The National Institutes of Health announced Thursday that it is launching the safety trial on a vaccine developed by the agency's National Institute of Allergy and Infectious Diseases and GlaxoSmithKline .

Comment?

Related Topix: Biotech, Medicine, GlaxoSmithKline, Healthcare Industry, Bethesda, MD

Wed Aug 27, 2014

Bloomberg

Glaxo's Ebola Vaccine to Be Tested for Safety in Humans

U.S. scientists will begin enrolling patients as soon as next week in clinical safety trials of GlaxoSmithKline Plc 's experimental Ebola vaccine as the death toll from the disease rises in West Africa.

Comment?

Related Topix: Biotech, Medicine, GlaxoSmithKline, Healthcare Industry, Food and Drug Administration

Tue Aug 26, 2014

Forbes.com

Use Options For a Chance To Buy BCRX at a 59% Discount

Options For Income is a contributor page created by the editors of Stock Options Channel, a stock options research Website.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, Financial Markets

Fri Aug 22, 2014

AmericanBankingNews.com

BioCryst Pharmaceuticals Receives Consensus Rating of "Buy" from Analysts

BioCryst Pharmaceuticals has earned a consensus rating of "Buy" from the twelve brokerages that are covering the company, Stock Ratings Network reports .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Tue Aug 19, 2014

Local Tech Wire

$4.1M federal grant could put BioCryst in Ebola fight - next time

It was not only a $4.1 million influx of additional federal research money to Durham drug development company BioCryst Pharmaceuticals.

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry, North Carolina, Epidemic, Natural Disasters

Mon Aug 18, 2014

AmericanBankingNews.com

BioCryst Pharmaceuticals Given Average Rating of "Buy" by Analysts

BioCryst Pharmaceuticals has received a consensus rating of "Buy" from the twelve analysts that are covering the stock, Stock Ratings Network reports .

Comment?

Related Topix: Biotech, Medicine, Healthcare Industry

Business Journal

Duke: Using experimental drug in Ebola outbreak could 'prove disastrous'

It's a debate federal regulators and drug companies have all the time. Should a company with an experimental drug give it to people in need to potentially save their lives, or should regulators make sure the drug is safe before it does any more harm? It's a question that seems to always result in a lose-lose situation.

Comment?

Related Topix: Medicine, Biotech, GlaxoSmithKline, Healthcare Industry

•••
•••
•••
•••

Woodbridge Jobs

•••
•••
•••
•••